column_value,column_name,value_count
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Developer,6
"National Research Centre, Egypt",Developer,4
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Developer,2
Intravacc/Epivax,Developer,2
Max-Planck-institute of Colloids and Interfaces,Developer,2
"Research Institute for Biological Safety Problems, Rep of Kazakhstan",Developer,2
Farmacologicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Developer,2
Fudan University/ y/Shangha iaoTong University/RNACure Biopharma,Developer,2
Erciyes University,Developer,2
"IDIBAPS-Hospita Clinic, Spain",Developer,2
University of Manitoba,Developer,2
Selcuk University,Developer,2
Cadila Healthcare Limited,Developer,2
Greffex,Developer,1
University of Hong Kong,Developer,1
AnyGo Technology,Developer,1
"West China Hospital, Sichuan University",Developer,1
Heat Biologics/Univ. Of Miami,Developer,1
Israel Institute for Biologica Research/Weizmann Institute of Science,Developer,1
Fundacao Oswaldo Cruz and Instituto Buntantan,Developer,1
DIOSynVax Ltd / University of Cambridge,Developer,1
Baiya Phytopharm/ Chula Vaccine Research Center,Developer,1
"Instituto Finlay de Vacunas, Cuba",Developer,1
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme,Developer,1
Entos Pharmaceuticals,Developer,1
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,Developer,1
"MOGAM Institute for Biomedical Research, GC Pharma",Developer,1
Osaka University/ AnGes/ /Takara Bio,Developer,1
MIGAL Galilee Research Institute,Developer,1
"Beijing Minhai Biotechnology Co., Ltd.",Developer,1
Arcturus/Duke-NUS,Developer,1
iBio/cc-Pharming,Developer,1
AdaptVac (PREVENT-nCoV consortium),Developer,1
Clover Biopharmaceuticals Inc./GSK/Dynavax,Developer,1
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Developer,1
Ankara University,Developer,1
IMV Inc,Developer,1
Chula Vaccine Research Center,Developer,1
BiOMVis Sri/Univ. of Trento,Developer,1
Bharat Biotech/Thomas Jefferson University,Developer,1
University of Alberta,Developer,1
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation,Developer,1
Intravacc/Wageningen Bioveterinary Research/Utrecht Univ.,Developer,1
Aurobindo,Developer,1
OSIVAX,Developer,1
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria.",Developer,1
DZIF German Center for Infection Research/IDT Biologika GmbH,Developer,1
Beijing Institute of Biological Products/Sinopharm,Developer,1
BioNet Asia,Developer,1
Bogazici University,Developer,1
ExpreS2ion,Developer,1
"Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet",Developer,1
Neo7Logic,Developer,1
DZIF German Center for Infection Research/CanVirex AG,Developer,1
Greenlight Biosciences,Developer,1
"ImmunityBio, Inc. & Nantkwest, Inc.",Developer,1
"Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections",Developer,1
BIOCAD,Developer,1
Scancell/University of Nottingham/Nottingh Trent University,Developer,1
Translate Bio/Sanofi Pasteur,Developer,1
IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols,Developer,1
Genexine Consortium,Developer,1
University of Tokyo/ Daiichi-Sankyo,Developer,1
Mediphage Bioceuticals/Universit of Waterloo,Developer,1
University of Western Ontario,Developer,1
Mehmet Ali Aydinlar University / Acibadem Labmed Health Services A.S.,Developer,1
ARTES Biotechnology,Developer,1
Bharat Biotech,Developer,1
Doherty Institute,Developer,1
"Anhui Zhifei Longcom Biopharmaceutical/institute of Microbiology, Chinese Academy of Sciences",Developer,1
Gennova,Developer,1
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis,Developer,1
Saint-Petersburg scientific research institute of vaccines and serums,Developer,1
OSE immunotherapeutics,Developer,1
EpiVax,Developer,1
Inovio Pharmaceuticals/ International Vaccine Institute,Developer,1
Valo Therapeutics Ltd,Developer,1
Symvivo,Developer,1
University of Queensland/CSL/Seqirus,Developer,1
Univ. of Pittsburgh,Developer,1
Vaxine Pty Ltd/Medytox,Developer,1
Generex/EpiVax,Developer,1
ReiThera/LEUKOCARE/Univercells,Developer,1
Gamaleya Research Institute,Developer,1
Flow Pharma Inc,Developer,1
UW-Madison/FluGen/Bharat Biotech,Developer,1
Altimmune,Developer,1
Tonix Pharma/Southern Research,Developer,1
Axon Neuroscience SE,Developer,1
Biologica E Ltd,Developer,1
Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital,Developer,1
Baylor College of Medicine,Developer,1
Stabilitech Biopharma Ltd,Developer,1
University of Georgia/University of lowa,Developer,1
Quadram Institute Biosciences,Developer,1
Codagenix/Serum Institute of India,Developer,1
"RNAimmune, Inc.",Developer,1
"Navarrabiomed, Oncoimmunology group",Developer,1
Innovax/Xiamen Univ./GSK,Developer,1
AJ Vaccines,Developer,1
CanSino Biological Inc./Beijing Institute of Biotechnology,Developer,1
VBI Vaccines Inc.,Developer,1
"VIDO-InterVac, University of Saskatchewan",Developer,1
Izmir Biomedicine and Genome Center,Developer,1
Janssen Pharmaceutical Companies,Developer,1
Imperial College London,Developer,1
"University of San Martin and CONICET, Argentina",Developer,1
University of Oxford/AstraZeneca,Developer,1
"National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO, Thailand",Developer,1
Imophoron Ltd and Bristol University's Max Planck Centre,Developer,1
Neovii/Tel Aviv University,Developer,1
CanSino Biologics/Precision NanoSystems,Developer,1
eTheRNA,Developer,1
EpiVax/Univ. of Georgia,Developer,1
"National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma",Developer,1
Wuhan Institute of Biological Products/Sinopharm,Developer,1
Moderna/NIAID,Developer,1
University of Virginia,Developer,1
Takis/Applied DNA Sciences/Evvivax,Developer,1
"Chulalongkorn University/GPO, Thailand",Developer,1
China CDC/Tongji University/Stermina,Developer,1
KU Leuven,Developer,1
GeoVax/BravoVax,Developer,1
Mynvax,Developer,1
Medicago Inc.,Developer,1
Yisheng Biopharma,Developer,1
BiOCAD and IEM,Developer,1
"Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan",Developer,1
Indian Immunologicals Ltd/Griffith University,Developer,1
Univ. of Sao Paulo,Developer,1
Chula Vaccine Research Center/University of Pennsylvania,Developer,1
Vaxil Bio,Developer,1
Novavax,Developer,1
Valneva/Dynavax,Developer,1
ID Pharma,Developer,1
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.,Developer,1
WRAIR/USAMRIID,Developer,1
Curevac,Developer,1
Middle East Technical University,Developer,1
IAVI/Merck,Developer,1
"The Lancaster University, UK",Developer,1
Karolinska Institute / Cobra Biologics (OPENCORONA Project),Developer,1
KM Biologics,Developer,1
Sinovac/Dynavax,Developer,1
ImmunoPrecise/LiteVax BV,Developer,1
OncoGen,Developer,1
"Kentucky Bioprocessing, Inc",Developer,1
Vabiotech,Developer,1
Saiba GmbH,Developer,1
Sanofi Pasteur/GSK,Developer,1
"LakePharma, Inc.",Developer,1
BioNTech/Fosun Pharma/Pfizer,Developer,1
Bezmialem Vakif University,Developer,1
Vaxart,Developer,1
Lomonosov Moscow State University,Developer,1
Ege University,Developer,1
Sinovac,Developer,1
"Applied Biotechnology Institute, Inc.",Developer,1
Protein Subunit,Platform,63
Non-Replicating Viral Vector,Platform,23
RNA,Platform,23
Replicating Viral Vector,Platform,19
DNA,Platform,16
Inactivated,Platform,15
VLP,Platform,14
Live Attenuated Virus,Platform,3
T-cell based,Platform,1
Replicating Bacteria Vector,Platform,1
Inactivated,Candidate Type,9
mRNA,Candidate Type,8
VLP,Candidate Type,3
Protein Subunit,Candidate Type,3
LNP-mRNA,Candidate Type,3
VSV-S,Candidate Type,3
Peptide,Candidate Type,3
Codon deoptimized live attenuated vaccines,Candidate Type,3
DNA vaccine,Candidate Type,3
S protein,Candidate Type,2
Inactivated + CpG 1018,Candidate Type,2
Recombinant S protein,Candidate Type,2
DNA with electroporation,Candidate Type,2
OMV-based vaccine,Candidate Type,2
Measles Vector,Candidate Type,2
LNP-encapsulated mRNA,Candidate Type,2
RBD-based,Candidate Type,2
Ad5 S (GREVAXTM platform),Candidate Type,1
MVA-S encoded,Candidate Type,1
Enveloped Virus-Like Particle (eV/LP),Candidate Type,1
Recombinant S protein in IC-BEVS,Candidate Type,1
Recombinant spike protein with Essai O/W 1849101 adjuvant,Candidate Type,1
Attenuated Influenza expressing an antigenic portion of the Spike protein,Candidate Type,1
parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,Candidate Type,1
Horsepox vector expressing S protein,Candidate Type,1
Measles-vector based,Candidate Type,1
Spike-based (epitope screening),Candidate Type,1
Molecular clamp stabilized Spike protein with MF59 adjuvant,Candidate Type,1
DNA,Candidate Type,1
Newcastle disease virus vector (NDV-SARS- CoV-2/Spike),Candidate Type,1
Peptide antigens formulated in LNP,Candidate Type,1
COVID-19 XWG-03 truncated S (spike) proteins,Candidate Type,1
Adjuvanted recombinant protein (RBD-Dimer),Candidate Type,1
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,Candidate Type,1
eVLP,Candidate Type,1
Sendai virus vector,Candidate Type,1
3 LNP-mRNAs,Candidate Type,1
Peptides,Candidate Type,1
Adenovirus-based,Candidate Type,1
Nanoparticle vaccine,Candidate Type,1
Spike-based,Candidate Type,1
"Measles Virus (S, N targets)",Candidate Type,1
Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M,Candidate Type,1
Adeno5-based,Candidate Type,1
TBD,Candidate Type,1
Self-amplifying RNA,Candidate Type,1
DNA plasmid vaccine,Candidate Type,1
Oral Ad5 S,Candidate Type,1
Outer Membrane Vesicle (OMV)-subunit,Candidate Type,1
Several mRNA candidates,Candidate Type,1
RBD + Adjuvant,Candidate Type,1
"Virus-like particle, based on RBD displayed on virus-like particles",Candidate Type,1
MVA-S,Candidate Type,1
Protein Subunit EPV-CoV-19,Candidate Type,1
S-2P protein + CpG 1018,Candidate Type,1
adenovirus-based NasoVAx expressing SARS2-CoV spike protein,Candidate Type,1
li-Key peptide,Candidate Type,1
Adjuvanted microsphere peptide,Candidate Type,1
RBD-protein,Candidate Type,1
microneedle arrays S1 subunit,Candidate Type,1
Replicating Defective SARS-CoV-2 derived RNAs,Candidate Type,1
LNP-encapsulated mRNA cocktail encoding VLP,Candidate Type,1
bacTRL-Spike,Candidate Type,1
Recombinant S1-Fc fusion protein,Candidate Type,1
MVA expressing structural proteins,Candidate Type,1
Liposome-encapsulated mRNA,Candidate Type,1
S protein +Adjuvant,Candidate Type,1
LNP-nCOVsaRNA,Candidate Type,1
RBD protein fused with Fc of IgG + Adj.,Candidate Type,1
ChAdOx1-S,Candidate Type,1
Adjuvanted protein subunit (RBD),Candidate Type,1
Synthetic Long Peptide Vaccine candidate for S and M proteins,Candidate Type,1
Inactivated + alum,Candidate Type,1
s protein,Candidate Type,1
Replicating VSV vector-based DC-targeting,Candidate Type,1
Whole-Virion Inactivated,Candidate Type,1
Ora Vaccine platform,Candidate Type,1
gp-96 backbone,Candidate Type,1
"Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",Candidate Type,1
Subunit vaccine,Candidate Type,1
Adeno-based (rAd26-S+rAd5-S),Candidate Type,1
"Virus-like particles, lentivirus and baculovirus vehicles",Candidate Type,1
Recombinant deactivated rabies virus containing S1,Candidate Type,1
RBD (baculovirus production expressed in Sf9 cells),Candidate Type,1
"Subunit protein, plant produced",Candidate Type,1
Influenza A H1N1 vector,Candidate Type,1
S1 or RBD protein,Candidate Type,1
Unknown,Candidate Type,1
Capsid-like Particle,Candidate Type,1
structurally modified spherical particles of the tobacco mosaic virus (TMV),Candidate Type,1
Peptides derived from Spike protein,Candidate Type,1
Inactivated whole virus,Candidate Type,1
M2-deficient single replication (M2SR) influenza vector,Candidate Type,1
"Protein Subunit S,N,M&S1 protein",Candidate Type,1
YF17D Vector,Candidate Type,1
Recombinant spike protein with AdvaxM adjuvant,Candidate Type,1
"Orally delivered, heat stable subunit",Candidate Type,1
VLP-recombinant protein + Adjuvant,Candidate Type,1
S protein integrated in HIV VLPS,Candidate Type,1
Outer Membrane Vesicle(OMV)-peptide,Candidate Type,1
Replication-competent VSV chimeric virus technology (VSVAG) delivering the SARS-CoV- 2 Spike (S) glycoprotein.,Candidate Type,1
Replication defective Simian Adenovirus (GRAd) encoding S,Candidate Type,1
"DNA plasmid vaccine S,S1,S2,RB[ &N",Candidate Type,1
Plant-based subunit (RBD-Fc Adjuvant),Candidate Type,1
DNA plasmid vaccine with electroporation,Candidate Type,1
RBD protein (baculovirus production) -+ FAR- Squalene adjuvant,Candidate Type,1
Adenovirus Type 5 Vector,Candidate Type,1
Native like Trimeric subunit Spike Protein vaccine,Candidate Type,1
Drosophila S2 insect cel expression system VLPS,Candidate Type,1
VSV vector,Candidate Type,1
VLP + Adjuvant,Candidate Type,1
Oral E. coli-based protein expression system of s and N proteins,Candidate Type,1
Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal),Candidate Type,1
MVA encoded VLP,Candidate Type,1
Plant-derived VLP adjuvanted with GSK or Dynavax adjs.,Candidate Type,1
DNA plasmid vaccine RBD&N,Candidate Type,1
"DNA, engineered vaccine inserts compatible with multiple delivery systems",Candidate Type,1
LNP-encapsulated mRNA encoding S,Candidate Type,1
VLPS peptides/whole virus,Candidate Type,1
DNA plasmid vaccine + Adjuvant,Candidate Type,1
S subunit intranasal liposomal formulation with GLA/3M052 adjs.,Candidate Type,1
"2nd Gen E2b- Ad5 Spike, RBD, Nucleocapsid Subcutaneous&oral",Candidate Type,1
LNP-encapsulated mRNA encoding RBD,Candidate Type,1
adenovirus-based + HLA-matched peptides,Candidate Type,1
DNA Vaccine (GX-19),Candidate Type,1
ADDomerTM multiepitope display,Candidate Type,1
Virus-like particle-based Dendritic Cell(DC)- targeting vaccine,Candidate Type,1
Influenza vector expressing RBD,Candidate Type,1
Recombinant protein,Candidate Type,1
Adeno-associated virus vector (AAVCOVID),Candidate Type,1
"S-Protein (Subunit) + Adjuvant, E coli based Expression",Candidate Type,1
S protein (baculovirus production),Candidate Type,1
"Plasmid DNA, Needle-Free Delivery",Candidate Type,1
Ad26COVS1,Candidate Type,1
MsDNA vaccine,Candidate Type,1
Peptide + nove adjuvant,Candidate Type,1
Avian paramyxovirus vector (APMV),Candidate Type,1
Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD,Candidate Type,1
"Recombinant protein, nanoparticles (based on S-protein and other epitopes)",Candidate Type,1
"CD8 T cell peptide targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins",Candidate Type,1
mRNA in an intranasal delivery system,Candidate Type,1
TBD,Dose Count,145
2,Dose Count,26
1,Dose Count,4
3,Dose Count,1
1 or 2,Dose Count,1
2 or 3,Dose Count,1
TBD,Dose Timing,150
"0,28 days",Dose Timing,11
"0,21 days",Dose Timing,8
"0,14 days",Dose Timing,3
"0,14 or 0,21 days",Dose Timing,2
"0,28 or 0,28,56 days",Dose Timing,1
"0,56 days",Dose Timing,1
"0,14 or 0,28 days",Dose Timing,1
"0,28,56 days",Dose Timing,1
TBD,Route,144
IM,Route,32
ID,Route,2
IFV/COR/04,Phase 1 Desc,1
NCT04527575,Phase 1 Desc,1
NCT04453852,Phase 1 Desc,1
NCTO4283461 Interim Report,Phase 1 Desc,1
ISRCTN17072692,Phase 1 Desc,1
ChiCTR2000037518,Phase 1 Desc,1
NCTO4528641,Phase 1 Desc,1
NCT04436471 NCT04437875 Study Report,Phase 1 Desc,1
ChiCTR2000030906 Study Report,Phase 1 Desc,1
NCT04497298,Phase 1 Desc,1
NCT04412538,Phase 1 Desc,1
ACTRN12620000674932p,Phase 1 Desc,1
NCT04449276,Phase 1 Desc,1
ChiCTR2000034112,Phase 1 Desc,1
NCT04487210,Phase 1 Desc,1
NCTO4450004,Phase 1 Desc,1
NCT04405908,Phase 1 Desc,1
NCT04445194,Phase 1 Desc,1
NCT04473690,Phase 1/2 Desc,1
NCT04471519,Phase 1/2 Desc,1
NCT04383574 NCT04352608,Phase 1/2 Desc,1
2020-001038-36 ChiCTR2000034825 NCT04537949 Study Report,Phase 1/2 Desc,1
NCT04436276,Phase 1/2 Desc,1
PACTR202006922165132 2020-001072-15 Interim Report,Phase 1/2 Desc,1
NCT04470609,Phase 1/2 Desc,1
NCTO4445389,Phase 1/2 Desc,1
CTRI/2020/07/026352,Phase 1/2 Desc,1
ChiCTR2000031809 Interim Report,Phase 1/2 Desc,1
NCT04368988 Study Report,Phase 1/2 Desc,1
ChiCTR2000032459,Phase 1/2 Desc,1
NCT04447781 NCTO4336410,Phase 1/2 Desc,1
NCT04530357,Phase 1/2 Desc,1
NCT04480957,Phase 1/2 Desc,1
NCT04463472 NCTO4527081,Phase 1/2 Desc,1
NCTO4537208,Phase 1/2 Desc,1
NCT04533399 (phase 2b),Phase 2 Desc,1
NCT04405076,Phase 2 Desc,1
NCT04466085,Phase 2 Desc,1
NCT04515147,Phase 2 Desc,1
ChiCTR2000031781 Study Report,Phase 2 Desc,1
2020-001228-32,Phase 2 Desc,1
ChiCTR2000034780,Phase 3 Desc,2
NCT04456595 669/UN6.KEP/EC/2020,Phase 3 Desc,1
NCT04505722 (not yet recruiting),Phase 3 Desc,1
NCT04526990,Phase 3 Desc,1
NCT04470427,Phase 3 Desc,1
ISRCTN89951424 NCT04516746,Phase 3 Desc,1
NCT04530396,Phase 3 Desc,1
NCT04368728,Phase 3 Desc,1
Pre-Clinical,Clinical Phase,144
Phase 1,Clinical Phase,12
Phase 1/2,Clinical Phase,10
Phase 3,Clinical Phase,9
Phase 2,Clinical Phase,3
Pre-Clinical,Clinical Stage,144
Clinical,Clinical Stage,34
SARS-CoV2,Coronavirus Target,174
SARS-CoV2 and Sarbeco- Coronaviruses,Coronavirus Target,1
SARS-CoV1 SARS-CoV2,Coronavirus Target,1
Pan-Corona,Coronavirus Target,1
"SARS-CoV2, SARS-CoV, & MERS-CoV",Coronavirus Target,1
Influenza,Shared Platforms,6
MERS,Shared Platforms,4
SARS,Shared Platforms,2
Multiple candidates,Shared Platforms,1
"HAV, InfA, ZIKV, FMD, SIV, RSV, DENV",Shared Platforms,1
malaria,Shared Platforms,1
"flu, Chik, Zika, EBOV, LASV, HIV/SIV,Can V,Cancer",Shared Platforms,1
HPV/,Shared Platforms,1
"InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE",Shared Platforms,1
"rubella, rotavirus",Shared Platforms,1
"Smallpox, monkeypox",Shared Platforms,1
"HIV, MERS",Shared Platforms,1
Hepatitis C,Shared Platforms,1
"Zika, H7N9, CHIKV",Shared Platforms,1
Many,Shared Platforms,1
"Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine",Shared Platforms,1
"Zika, VZV, HSV-2 and Norovirus",Shared Platforms,1
"HeV, NiV, EBOV, LASSA, CCHFV, MERS",Shared Platforms,1
"JE, Zika",Shared Platforms,1
"NSCLC, HIV, malaria, Zika",Shared Platforms,1
"Influenza, HIV, SARS-CoV",Shared Platforms,1
H7N9,Shared Platforms,1
"Ebola, Marburg, Lassa",Shared Platforms,1
"LASV, EBOV, MARV, HIV",Shared Platforms,1
"Flu A, plague",Shared Platforms,1
"CMV, GBM, Zika",Shared Platforms,1
